Complete Response Letter

Last updated

In United States pharmaceutical regulatory practice, a Complete Response Letter (CRL), or more rarely, a 314.110 letter, is a regulatory action by the Food and Drug Administration in response to a New Drug Application, Amended New Drug Application or Biologics License Application, indicating that the application will not be approved in its present form. [1] CRLs replaced approvable letters in 2018.

Contents

Background

Under the Prescription Drug User Fee Act, the Food and Drug Administration has a limited timespan (known as the PDUFA date) to decide a New Drug Application, Amended New Drug Application or Biologics License Application. The FDA may either approve the application or issue a Complete Response Letter. [2] Grounds behind issuing a CRL may include labelling issues, current Good Manufacturing Practice concerns or concerns about the safety or effectiveness of the drug. [3]

A sponsor receiving CRL may withdraw the application, request a hearing or resubmit the application. [1] Because hearings are open to the public, this course of action is relatively rarely chosen. [4]

Class 1 and Class 2 resubmissions after CRLs

MAPP 6020 Rev. 2, the Food and Drug Administration policy manual governing resubmissions following a CRL, classifies CRLs as requiring a Class 1 or Class 2 resubmission. [5] Where a sponsor decides to submit a response to a CRL, the response is classified within 30 days, if the response is complete. [6] A Class 1 response typically denotes minor amendments, such as labelling, assay validation data or minor re-analysis of the data supporting the application, while a Class 2 response typically involves more extensive concerns and/or a reinspection. [6] A Class 1 response is typically handled within 3 months, while a Class 2 response is typically handled within 6 months. [5]

Economic impact

A CRL frequently has a significant impact on the sponsor's share price. Orphazyme, a Danish biopharmaceutical company, lost over half of its share value overnight upon disclosing a CRL for arimoclomol, a proposed treatment for Niemann–Pick disease, type C, [7] forcing the company to restructure. [8] BioMarin Pharmaceutical lost over 30% of its value when a CRL was issued in respect of its hemophilia A gene therapy, valoctocogene roxaparvovec. [9] Sesen Bio's stock price dropped over 80% after reporting a CRL for Vicineum as a treatment for a type of bladder cancer. [10]

Disclosure

Typically, CRLs are not disclosed publicly as they often include proprietary information. [11] Press releases, when issued, typically do not include most of the details contained in the CRL, including the reasons behind it. [12] While there is no general obligation to publicly disclose a CRL's existence or contents, the U.S. Securities and Exchange Commission has in the past brought action against companies that allegedly misled investors about a CRL. [13]

Related Research Articles

The Online Certificate Status Protocol (OCSP) is an Internet protocol used for obtaining the revocation status of an X.509 digital certificate. It is described in RFC 6960 and is on the Internet standards track. It was created as an alternative to certificate revocation lists (CRL), specifically addressing certain problems associated with using CRLs in a public key infrastructure (PKI). Messages communicated via OCSP are encoded in ASN.1 and are usually communicated over HTTP. The "request/response" nature of these messages leads to OCSP servers being termed OCSP responders.

<span class="mw-page-title-main">Allura Red AC</span> Chemical compound

Allura Red AC is a red azo dye that goes by several names, including FD&C Red 40. It is used as a food dye and has the E number E129.

<span class="mw-page-title-main">Home Mortgage Disclosure Act</span> United States federal law

The Home Mortgage Disclosure Act is a United States federal law that requires certain financial institutions to provide mortgage data to the public. Congress enacted HMDA in 1975.

The Lower Thames Crossing is a proposed road crossing of the Thames estuary downstream of the Dartford Crossing that links the counties of Kent and Essex, and its proposed approaches. If built it would pass through the districts of Thurrock and Gravesham, supplementing the Dartford route. The approximately 14.3-mile (23.0 km) route will be assessed by the Planning Inspectorate.

Drug Master File or DMF is a document prepared by a pharmaceutical manufacturer and submitted solely at its discretion to the appropriate regulatory authority in the intended drug market. There is no regulatory requirement to file a DMF. However, the document provides the regulatory authority with confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. Typically, a drug master file is filed when two or more firms work in partnership on developing or manufacturing a drug product. The DMF filing allows a firm to protect its intellectual property from its partner while complying with regulatory requirements for disclosure of processing details.

<span class="mw-page-title-main">State University of New York Upstate Medical University</span> Medical school of SUNY Upstate

The State University of New York Upstate Medical University is a public medical school in Syracuse, New York. Founded in 1834, Upstate is the 15th oldest medical school in the United States and is the only medical school in Central New York. The university is part of the State University of New York (SUNY) system.

<span class="mw-page-title-main">Prescription Drug User Fee Act</span> Legislation in the United States

The Prescription Drug User Fee Act (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process. The Act provided that the FDA was entitled to collect a substantial application fee from drug manufacturers at the time a New Drug Application (NDA) or Biologics License Application (BLA) was submitted, with those funds designated for use only in Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) drug approval activities. In order to continue collecting such fees, the FDA is required to meet certain performance benchmarks, primarily related to the speed of certain activities within the NDA review process.

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

<span class="mw-page-title-main">Phentermine/topiramate</span> Obesity medication

Phentermine/topiramate, sold under the brand name Qsymia, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped. The weight loss is modest. Effects on heart related health problems or death is unclear.

The U.S. Food and Drug Administration (FDA) is authorized to perform inspections under the Federal Food, Drug, and Cosmetic Act, Sec. 704 "Factory Inspection". Form FDA 483, "Inspectional Observations", is a form used by the FDA to document and communicate concerns discovered during these inspections. Also referred to as "Form 483" or merely "483", it states thereon that it

... lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance

An FDA warning letter is an official message from the United States Food and Drug Administration (FDA) to a manufacturer or other organization that has violated some rule in a federally regulated activity.

<span class="mw-page-title-main">React (software)</span> JavaScript library for building user interfaces

React is a free and open-source front-end JavaScript library for building user interfaces based on components. It is maintained by Meta and a community of individual developers and companies.

Approvable letters, and the related non-approvable letters, were notifications sent out by the Food and Drug Administration (FDA) to drug manufacturers alerting them to the approval prospects of their drugs under development. The letters were intended to let manufacturers know how much work is needed on their applications. Non-approval letters were rejections of a drug's application. Approvable and non-approvable letters were covered under Title 21 of the Code of Federal Regulations, section 314.110.

<span class="mw-page-title-main">Iqos</span> Heated tobacco products by Philip Morris International

Iqos is a line of heated tobacco and electronic cigarette products manufactured by Philip Morris International (PMI). It was first introduced in November 2014 in Japan and Italy. Most of the IQOS products are devices that heat tobacco without burning it.

<span class="mw-page-title-main">MVC COVID-19 vaccine</span> Vaccine against COVID-19

The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies, and the U.S. National Institutes of Health.

Regenerative Medicine Advanced Therapy (RMAT) is a designation given by the Food and Drug Administration to drug candidates intended to treat serious or life-threatening conditions under the 21st Century Cures Act. A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints.

RVT-802 is a medication being developed by Enzyvant Therapeutics Ireland Limited for the treatment of congenital athymia, especially in the context of DiGeorge syndrome.

In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application. It is part of the regime established by the Prescription Drug User Fee Act to ensure funding of the Food and Drug Administration's drug approval activities in return for adhering to a largely fixed timetable of regulatory actions.

A first-in-class medication is a pharmaceutical that uses a "new and unique mechanism of action" to treat a particular medical condition. While the Food and Drug Administration's Center for Drug Evaluation and Research tracks first-in-class medications and reports on them annually, first-in-class is not considered a regulatory category. Although many first-in-class medications qualify as breakthrough therapies, Regenerative Medicine Advanced Therapies and/or orphan drugs, first-in-class status itself has no regulatory effect.

<span class="mw-page-title-main">Sakura Samurai (group)</span> Hacker group

Sakura Samurai was a white hat hacking and security research group that was founded in 2020. The group is responsible for multiple vulnerability disclosures involving governmental groups and various corporations.

References

  1. 1 2 "21 CFR 314.110". www.accessdata.fda.gov. Retrieved 2021-06-30.{{cite web}}: CS1 maint: url-status (link)
  2. ↑ Thayer, Ann M. (15 May 2017). "The complete response letter: The mail no one wants to receive". ACS C&EN. Retrieved 2021-06-30.{{cite web}}: CS1 maint: url-status (link)
  3. ↑ Chandanais, Ryan (8 December 2017). "Complete Response Letters: What Drug Manufacturers Hope to Avoid". Pharmacy Times. Retrieved 2021-06-30.{{cite web}}: CS1 maint: url-status (link)
  4. ↑ "FDA Complete Response Letters: The design v. reality of FDA's responses to drug applications". Healthcare Law Insights. 2015-01-12. Retrieved 2021-06-30.
  5. 1 2 "MAPP 6020.5 Rev. 2: Classifying Resubmissions of original NDAs, BLAs and Efficacy Cupplements in Response to Complete Response Letters". Food and Drug Administration, Center for Drug Evaluation and Research. Retrieved 2021-06-30.
  6. 1 2 "MAPPing Out The Timing Of A Complete Response Submission". Camargo. 27 February 2015. Retrieved 2021-06-30.{{cite web}}: CS1 maint: url-status (link)
  7. ↑ Kilgore, Tomi. "Orphazyme stock plunges after receiving CRL from FDA after review of NPC treatment". MarketWatch. Retrieved 2021-06-30.
  8. ↑ ORPHAZYME A/S (2021-06-28). "Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC". GlobeNewswire News Room. Retrieved 2021-06-30.{{cite web}}: CS1 maint: url-status (link)
  9. ↑ Fox, Matthew (19 August 2020). "2 biotech stocks plummet more than 25% after the FDA rejects their drug applications". Business Insider . Retrieved 2021-06-30.{{cite web}}: CS1 maint: url-status (link)
  10. ↑ "FDA rejects Sesen Bio's bladder cancer pitch, sending shares spiraling back to penny stock territory". Endpoints News. Retrieved 2021-08-16.
  11. ↑ Mullard, Asher (2015-07-01). "Should the FDA disclose complete response letters?". Nature Reviews Drug Discovery. 14 (7): 449. doi: 10.1038/nrd4686 . ISSN   1474-1784. S2CID   34872830.
  12. ↑ Lurie, Peter; Chahal, Harinder S.; Sigelman, Daniel W.; Stacy, Sylvie; Sclar, Joshua; Ddamulira, Barbara (2015-06-10). "Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study". BMJ. 350: h2758. doi:10.1136/bmj.h2758. ISSN   1756-1833. PMC   4462714 . PMID   26063327.
  13. ↑ "SEC.gov | FCPA, Disclosure, and Internal Controls Issues Arising in the Pharmaceutical Industry". www.sec.gov. Retrieved 2021-06-30.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.